Annual report pursuant to Section 13 and 15(d)

Long-Term Debt and Other Financings - Novartis Note - Additional Information (Details)

v3.6.0.2
Long-Term Debt and Other Financings - Novartis Note - Additional Information (Details) - USD ($)
1 Months Ended 12 Months Ended
Jan. 31, 2014
May 31, 2005
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Novartis Note [Member]          
Debt Instrument [Line Items]          
Maturity date   Jun. 30, 2015      
Research and development expenses funded through loan facility, maximum   75.00%      
Maximum borrowing capacity under loan agreement   $ 50,000,000      
Interest rate at period end     3.32%    
Accrued interest payable     $ 400,000 $ 300,000 $ 300,000
Percentage of milestone received 25.00%        
Milestone received under the collaboration agreement $ 7,000,000        
Repayment of debt $ 1,750,000        
Outstanding principal balance     $ 14,100,000 $ 13,700,000  
Novartis Note [Member] | Six-month London Interbank Offered Rate [Member]          
Debt Instrument [Line Items]          
Basis spread on variable rate       2.00%  
Secured Note Amendment [Member]          
Debt Instrument [Line Items]          
Maturity date     Sep. 30, 2020    
Reduction in outstanding principal amount     $ 7,300,000